Keynote -564 is the first Phase 3 trial to demonstrate superior overall survival (OS) with adjuvant therapy compared to placebo in patients with RCC
This agreement includes upfront and milestone payments with a combined potential value of over $500m and sales royalties.
In the Phase 3 LIBRETTO-431 study, Retevmo more than doubled progression-free survival (PFS) compared to chemotherapy plus pembrolizumab in patients with advanced or metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC)
Lilly to further investigate retatrutide for the treatment of obesity in the TRIUMPH phase 3 clinical program
Clinic will offer Comprehensive Genetic Counselling and Testing Services to empower patients with personalized care
Launch of the Da Vinci Xi Robotic System is the highlight of the Robotic Colorectal Cancer Symposium organized with the Association of Colon and Rectal Surgeons of India
The award recognizes and supports promising female scientists working in mass spectrometry
The one-year-long study was aimed to evaluate the efficacy of LDH's digital therapeutics platform
AstraZeneca and Merck are committed to working with the FDA to bring LYNPARZA in combination with abi/pred to patients diagnosed with mCRPC.
Subscribe To Our Newsletter & Stay Updated
